Men with ANCA-associated vasculitis (AAV) have a 1.54 times higher risk of dying within one year than female patients, a new study finds. According to authors, “this [finding] may provide a reliable predictor for clinicians to judge the prognosis and select active treatment for patients with AAV.” The report,…
The number of ANCA-associated vasculitis (AAV) cases in Spain more than doubled between 2019 and 2021 following mass-scale vaccination against SARS-CoV-2, the virus that causes COVID-19, a new study found, suggesting the vaccine as a possible trigger. Researchers suspect the development of ANCA antibodies and AAV could be among…
The Johnson & Johnson COVID-19 vaccine may have triggered kidney inflammation associated with ANCA-associated vasculitis (AAV) in a 52-year-old woman, according to a recent case report. “We believe that this is the first case report of AAV that occurred following adenovirus vector COVID-19 vaccine administration,” its scientists wrote. “Increasing…
A 65-year-old man developed granulomatosis with polyangiitis (GPA), a type of anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), after receiving a stem cell transplant for another autoimmune condition, according to a case report. “[Our] case report suggests that [AAV] may develop in the setting of stem cell transplantation and must…
Many ANCA-associated vasculitis (AAV) patients with skin lesions test negative for ANCA antibodies — proteins produced by the immune system that bind to white blood cells called neutrophils, ultimately triggering an autoimmune reaction. As a result, researchers contend that ANCA testing should not be used as the only criteria…
People with a past history of autoimmune disease before developing ANCA-associated vasculitis (AAV) have significantly fewer relapses after achieving remission, a study reported. Post-remission chances of a relapse were 67% lower in these AAV patients and took longer to occur, findings showed. Its researchers argued that these results support a…
Note: This story was updated Feb. 22, 2022, to update the headline and clarify that some patients on rituximab do not mount an effective T-cell response to the COVID-19 vaccine. A significant proportion of patients on rituximab, including those with …
Treatment with the CD20 inhibitor rituximab is significantly associated with poor antibody responses to COVID-19 vaccines among people with ANCA-associated vasculitis (AAV), a study found. However, the number of antibody-producing B-cells, the rituximab dose, and the timing between last rituximab administration and vaccination were all important factors determining how…
Blood levels of several proteins — CXCL13, interleukins IL-6, IL-8, IL-15, IL-18 binding protein (IL-18BP), matrix metalloproteinase-3 (MMP-3), and erythrocyte sedimentation rate (ESR) — were validated as effective at identifying active ANCA-associated vasculitis (AAV) in a long-term study. The study, “Serum Biomarkers of Disease Activity in Longitudinal Assessment…
Get regular updates to your inbox.